Is appearance-related social comparison a causal mechanism underlying appearance-related psychopathology among young adult women? An experimental test
Abstract
Appearance-related social comparisons (ARSCs) have been identified as a maladaptive process related to appearance concerns and symptoms of body dysmorphic disorder (BDD), social anxiety disorder (SAD), and eating disorders (EDs). The aim of the present study was to test the effects of fading (i.e., systematically reducing or eliminating) these behaviors using a non-treatment experimental design in which the study's purpose was concealed from participants. Women with elevated (i.e., upper quartile) appearance concerns (N = 100) were randomized to either a one-month text message-based ARSC fading condition (n = 50) or a ARSC self-monitoring control condition (n = 50). We found that relative to control, ARSC fading led to lower appearance concerns, appearance importance, BDD symptoms, ED symptoms, and trait anxiety. Further, changes in ARSCs mediated the effect of condition on appearance concerns, BDD symptoms, and ED symptoms. Compared to control, the ARSC fading group also demonstrated less reactivity to one of two in vivo appearance-related stressor tasks. We also explore the incremental role ARSCs contribute to outcomes over related behaviors (e.g., checking, avoidance, reassurance seeking). Importantly, few participants correctly guessed the purpose of the study, and their removal from analyses did not affect study findings. This study provides novel evidence for the importance of ARSCs in the maintenance of appearance-related psychopathology.
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 100 participants or records.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.